Threshold completes $34.7mm IPO
Executive Summary
Threshold Pharmaceuticals (focused on cancer therapeutics) has completed its IPO, netting $34.7mm with the sale of 5.33mm common shares at $7 each. The company had hoped to bring in up to $86.25mm when it originally filed in April 2004.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice